Bioactive Polymers for Wound Healing Applications. VitroGroR is a growth factor complex which enhances cell growth and migration, and hence has great potential for treating wounds. Tissue Therapies, which holds the rights to commercialization of VitroGroR, is seeking to develop methods of delivering VitroGroR in its active form to the wound environment. Two solutions to this problem will be developed in this project; a bioactive bandage containing a novel combination of microspheres and a hydrog ....Bioactive Polymers for Wound Healing Applications. VitroGroR is a growth factor complex which enhances cell growth and migration, and hence has great potential for treating wounds. Tissue Therapies, which holds the rights to commercialization of VitroGroR, is seeking to develop methods of delivering VitroGroR in its active form to the wound environment. Two solutions to this problem will be developed in this project; a bioactive bandage containing a novel combination of microspheres and a hydrogel matrix, and secondly an in-situ polymerisable matrix for treatment of deep wounds. The growth factor complex will be protected from aggressive proteases through encapsulation within microspheres, and the use of MMP-inhibiting comonomers.Read moreRead less
Bioreactors for manufacture of human platelets. Blood cell transfusion is a critical part of medicine that is supported by volunteer donors. Unfortunately, the demand for blood cells for transfusion far outstrips supply and therefore new strategies are required for manufacture of blood cells. This project will lead to the development of technology for manufacture of human platelets from stem cells. The systems devised will be applicable to a broad range of other blood cell types.
Special Research Initiatives - Grant ID: SR0354797
Funder
Australian Research Council
Funding Amount
$20,000.00
Summary
The Australian Tissue Engineering Network. Driven by four key nodes across the country, the Initiative aims to bring together geographically and financially separated groups into a critical mass of cell and tissue engineering research. This new and rapidly-growing field uses a bio-synthetic approach to replace, repair or regenerate damaged tissues and organs. The Initiative will build the framework which will enable the Network to: identify appropriate expertise, manage duplication, enhance co ....The Australian Tissue Engineering Network. Driven by four key nodes across the country, the Initiative aims to bring together geographically and financially separated groups into a critical mass of cell and tissue engineering research. This new and rapidly-growing field uses a bio-synthetic approach to replace, repair or regenerate damaged tissues and organs. The Initiative will build the framework which will enable the Network to: identify appropriate expertise, manage duplication, enhance communication, bring together innovative skill sets, create linkages, generate focussed research programs and foster novel commercial opportunities. Ultimately the Initiative and Network will deliver an improved quality of life, reduced healthcare costs, and increased productivity to Australia.Read moreRead less
Biomaterial applications of synthetic elastin. The grant will develop a new collaboration between two established laboratories. The Weiss Lab (synthetic elastin; University of Sydney, Australia) will send elastin materials to the Langer Lab (interface of biotechnology and materials science; MIT, USA). Prof. Weiss will visit the Langer Lab and be trained in and participate collaboratively in the use of established MIT methodologies that will focus on applications in cardiac tissue engineering, co ....Biomaterial applications of synthetic elastin. The grant will develop a new collaboration between two established laboratories. The Weiss Lab (synthetic elastin; University of Sydney, Australia) will send elastin materials to the Langer Lab (interface of biotechnology and materials science; MIT, USA). Prof. Weiss will visit the Langer Lab and be trained in and participate collaboratively in the use of established MIT methodologies that will focus on applications in cardiac tissue engineering, controlled release of drugs and vocal fold repair. The MIT group will benefit from access to and the use of elastin materials that are developed in AustraliaRead moreRead less
Discovery Early Career Researcher Award - Grant ID: DE170100398
Funder
Australian Research Council
Funding Amount
$410,507.00
Summary
How T cells modulate stem cells and tissue regeneration. The project aims to determine how T cells modulate tissue repair and regeneration in mammals. Most of the mechanisms modulating the healing of tissues are elusive. This research is expected to reveal unknown mechanisms controlling the processes of tissue repair and regeneration, particularly the nexus between the stem cells involved in the tissue healing process and the immune response .
The development of new scaffolds for bone repair comprising polycaprolactone and strontium-substituted bioactive glasses. The drive to develop bone grafts to fill major gaps in the skeleton, whilst circumventing the need to use permanent implants has led to a major research thrust towards developing biomaterials for bone-tissue engineering. The project will develop scaffolds with highly osteoconductive bioactive glasses in a polymer matrix for bone regeneration applications.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE180100200
Funder
Australian Research Council
Funding Amount
$270,427.00
Summary
AutoStem: a high performance, automated stem cell bioengineering facility. This project aims to establish an automated stem cell bioengineering ("AutoStem") facility that will enable critical insights into the molecular mechanisms that underly the loss in stem cell function and tissue homeostasis as we age. The AutoStem facility expects to lead to the discovery of the key drivers of stem cell ageing and the development of novel technological solutions to maintain tissue function with age. The o ....AutoStem: a high performance, automated stem cell bioengineering facility. This project aims to establish an automated stem cell bioengineering ("AutoStem") facility that will enable critical insights into the molecular mechanisms that underly the loss in stem cell function and tissue homeostasis as we age. The AutoStem facility expects to lead to the discovery of the key drivers of stem cell ageing and the development of novel technological solutions to maintain tissue function with age. The outcomes produced from the AutoStem facility will have significant economic and social benefits in enabling healthy ageing and increased productivity for an ageing Australia.Read moreRead less
Generating multi-component scaffolding to influence the differentiation of embryonic stem cells. Nervous system diseases are debilitating and will develop in over 50 per cent of people at some time in their life. This project will develop strategies so that stem cells can be utilised to encourage brain repair for the treatment of Parkinson's disease. The technology developed will also be of benefit for the treatment of other nervous system disorders.
Modulation of protein folding pathways: a new platform technology for molecular medicine. Misfolding of proteins is becoming recognised as a major cause of inherited disease. We propose to develop a chemical agent that will optimise the folding of alpha1-antitrypsin (AAT), misfolding of which gives rise to inheritable liver and lung disease. This agent will have potential application as a therapy for sufferers of AAT-misfolding disease and for improving the yield of AAT purified from human plasm ....Modulation of protein folding pathways: a new platform technology for molecular medicine. Misfolding of proteins is becoming recognised as a major cause of inherited disease. We propose to develop a chemical agent that will optimise the folding of alpha1-antitrypsin (AAT), misfolding of which gives rise to inheritable liver and lung disease. This agent will have potential application as a therapy for sufferers of AAT-misfolding disease and for improving the yield of AAT purified from human plasma, which is the current agent used to treat patients with AAT-misfolding disease.Read moreRead less
Bio-MEMS eye sensor for continuous monitoring of intraocular pressure. Glaucoma is a leading cause of preventable blindness, particularly prevalent in the 60+ population, caused by elevated intraocular pressure (IOP). Current treatment to monitor and prevent glaucoma-related blindness is by lowering IOP with eye-drops, laser therapy or surgery. This project directly benefits our aging population by ensuring independence and quality of life, whilst reducing long-term medical and social costs. By ....Bio-MEMS eye sensor for continuous monitoring of intraocular pressure. Glaucoma is a leading cause of preventable blindness, particularly prevalent in the 60+ population, caused by elevated intraocular pressure (IOP). Current treatment to monitor and prevent glaucoma-related blindness is by lowering IOP with eye-drops, laser therapy or surgery. This project directly benefits our aging population by ensuring independence and quality of life, whilst reducing long-term medical and social costs. By incorporating nanotechnology with ophthalmology we will provide an economic solution to long-term, reliable, home-monitoring of IOP. An implantable IOP sensor, will identify patients requiring more invasive treatment compared with those with less aggressive disease, leading to better health resource utilisation.Read moreRead less